Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy

The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Rakesh, Maier, Harald J., Zhang, Jie, Lim, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294746/
https://www.ncbi.nlm.nih.gov/pubmed/37185251
http://dx.doi.org/10.1080/21645515.2023.2210046
Descripción
Sumario:The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.

Ejemplares similares